This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Options Traders Expect Huge Moves in MannKind Corporation (MNKD) Stock
by Zacks Equity Research
MannKind Corporation (MNKD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in MannKind (MNKD) Stock
by Zacks Equity Research
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
by Zacks Equity Research
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
MannKind Corporation (MNKD) was a big mover last session, as the company saw its shares rise over 7% on the day amid huge volumes.
Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options
by Zacks Equity Research
MannKind Corp. (MNKD) warrants investors' attention based on moves in the options market lately.
Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA
by Zacks Equity Research
Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
by Zacks Equity Research
The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).
Galena Biopharma Reveals Regulatory Pathway for GALE-401
by Zacks Equity Research
Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.
Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
by Zacks Equity Research
Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
MannKind (MNKD) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in MannKind Corporation (MNKD).
Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
by Zacks Equity Research
Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.
Profit from These 5 Stocks with Rising P/E Ratio
by Zacks Equity Research
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Celgene (CELG) Otezla Approved in Japan for Two Indications
by Zacks Equity Research
Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.
3 Low P/E Momentum ETFs & Stocks for Uncertain Santa Rally
by Sanghamitra Saha
Can Santa cause a rally this year? If you have some hope, try these three 3 low P/E momentum ETFs and stocks.
Clovis Scales 52-Week High on Early FDA Nod for Rubraca
by Zacks Equity Research
Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.
Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars
by Ryan McQueeney
While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany, the U.S. indexes were all green on Monday.
Trovagene to Focus More on Liquid Biopsy Testing Market
by Zacks Equity Research
Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.
athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
by Zacks Equity Research
athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.
Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.
Envision Healthcare Acquires Desert Mountain Consultants
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.
Proteon Slips to 52-Week Low on Kidney Disease Study Data
by Zacks Equity Research
Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.
Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger
by Zacks Equity Research
Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger
Buy 5 Stocks with Rising P/E to Bust a Common Myth
by Zacks Equity Research
Forget undervalued stocks, buy these top-ranked stocks with rising P/E.
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
by Zacks Equity Research
Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.